Bicara Therapeutics (BCAX) Cash from Investing Activities (2023 - 2026)

Bicara Therapeutics' Cash from Investing Activities history runs 4 years deep, the most recent figure standing at $100.9 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities changed N/A year-over-year to $100.9 million; the TTM figure through Mar 2026 stood at -$217.5 million (down 324546.27% YoY), while the FY2025 annual figure was -$318.5 million, down 3538266.67% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $100.9 million, up from -$82.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $100.9 million in Q1 2026, with the low at -$236.1 million in Q3 2025.
• The 4-year median for Cash from Investing Activities is -$29500.0 (2024), against an average of -$27.2 million.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities jumped 90.83% in 2024, then plunged 2951412.5% in 2025.
• Bicara Therapeutics' Cash from Investing Activities stood at -$436000.0 in 2023, then surged by 90.83% to -$40000.0 in 2024, then plunged by 205730.0% to -$82.3 million in 2025, then surged by 222.6% to $100.9 million in 2026.
• Business Quant data shows BCAX's Cash from Investing Activities at $100.9 million in Q1 2026, -$82.3 million in Q4 2025, and -$236.1 million in Q3 2025.